Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Partially aligned with the provided label excerpts: several core pharmacology and interaction claims (HMG-CoA reductase mechanism, hepatic LDL receptor increase, CYP3A4 metabolism, grapefruit juice interaction, and myopathy risk with specific interacting drugs) are supported. However, multiple wine/alcohol-specific claims are not supported by the provided label text, and some general statements (e.g., that statins are “processed by the liver”) are not explicitly stated in the excerpts.
Category Scores
Accurate Statements
Lipitor (atorvastatin) lowers cholesterol by inhibiting the liver’s cholesterol-making enzyme (HMG-CoA reductase).
Supported: 12.1 Mechanism of Action (inhibition of HMG-CoA reductase; cholesterol synthesis in liver).
Lipitor increases LDL receptor activity to clear LDL from the blood.
Supported: 12.1 Mechanism of Action (increases hepatic LDL receptors to enhance uptake/catabolism of LDL).
Atorvastatin is a substrate of CYP3A4.
Supported: 7.1 Strong Inhibitors of CYP 3A4 (metabolized by cytochrome P450 3A4).
Grapefruit juice significantly raises atorvastatin levels by inhibiting CYP3A4.
Supported: 7.2 Grapefruit Juice (components inhibit CYP3A4; increases plasma concentrations, especially with excessive intake).
Statin interactions can increase side-effect risk when combined with other lipid-lowering drugs (fibrates, niacin, etc.).
Supported (increased myopathy risk with concurrent lipid-modifying doses of niacin and fibric acid derivatives): 5.1 Skeletal Muscle and 7 (Drug Interactions).
Lipid-lowering drug combinations can increase side-effect risk.
Supported: 5.1 Skeletal Muscle (increased risk with concurrent administration of specific drugs including fibric acid derivatives and niacin).
Unsupported Statements
Wine does not change the way Lipitor lowers cholesterol.
Not supported by the provided label excerpts; no statement addressing wine’s effect on Lipitor’s cholesterol-lowering mechanism.
Alcohol (ethanol) in wine is processed by the liver.
No supporting statement about ethanol processing in the provided label excerpts.
Statins are processed by the liver.
Not explicitly stated as a general proposition in the provided excerpts (only cholesterol synthesis in liver and CYP metabolism are described).
Moderate wine intake is not expected to meaningfully interfere with Lipitor’s cholesterol-lowering mechanism for many people.
Not addressed in the provided label excerpts (no wine dosing/amount discussion or interference claim).
Wine may slightly raise HDL (the “good” cholesterol) on its own, separate from the statin effect.
No label statement about wine increasing HDL.
Wine is not the same as grapefruit juice and is not known to cause the same strong interaction.
Not addressed in the provided label excerpts.
Combining statins with other medications that increase the risk of muscle injury (myopathy/rhabdomyolysis) when taken with alcohol can increase risk.
Label provided increases myopathy risk with specific interacting drugs (e.g., fibric acid derivatives, niacin, cyclosporine, strong CYP3A4 inhibitors), but does not tie increased muscle-injury risk specifically to coadministration with alcohol.
Liver issues warning signs include unusual fatigue, weakness, jaundice, and dark urine.
No provided label excerpt lists these specific liver warning-sign symptoms.
Contradictions
Low
AI Statement
None identified as direct contradictions of the provided label excerpts.
Label Reference
Important Omissions
Potentially material safety content may be missing from the AI response, but cannot be evaluated because the full AI-generated response and complete label sections (e.g., Contraindications [4], Boxed Warnings if any, Use in Specific Populations [8], Dosage and Administration [2], and any additional warnings) are not provided in the audit inputs.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Multiple wine/alcohol-specific claims are not supported by the provided label excerpts (including specific interaction/avoidance framing). Additionally, label-driven safety counseling about liver dysfunction and muscle effects is not fully verified against the complete label due to incomplete section availability.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several alcohol/wine-related statements are not supported by the provided FDA label excerpts, including claims about wine effects on Lipitor’s mechanism, HDL, and specific interaction analogies to grapefruit juice; and a medication+alcohol muscle-injury risk linkage not present in the label excerpts.
Suggested Improvement
Remove or rephrase wine/alcohol claims unless supported by the full prescribing information; limit statements to label-supported guidance on alcohol caution in liver dysfunction and label-supported interacting agents (e.g., strong CYP3A4 inhibitors, fibric acid derivatives, niacin). Provide the full AI response and complete label text/sections to verify omissions and dosing/contraindication adherence.